MoonLake Q3 R&D expenses rise 37% quarter over quarter to $68.9 million

Bitget2026/11/04 12:15

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

MoonLake’s third-quarter 2026 R&D expenses rose 37% quarter-over-quarter to $68.9 million, while general and administrative expenses fell to $11 million.
Cash, cash equivalents and short-term marketable debt securities totaled $498.5 million at September 30, with cash runway expected through mid-2028.
A sonelokimab application for hidradenitis suppurativa was submitted to the FDA; a US launch is expected in H2 2027, if approved.
Sonelokimab 60 mg with induction met all Week 16 clinical endpoints in IZAR-1; initial IZAR-2 results are expected in Q1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moonlake Immunotherapeutics published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040700PRIMZONEFULLFEED1001301616) on November 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

MoonLake Q3 R&D expenses rise 37% quarter over quarter to $68.9 million

You may also like

Crypto prices